Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
0.831
-0.006 (-0.68%)
Feb 21, 2025, 4:00 PM EST - Market closed
Spero Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Spero Therapeutics stock have an average target of 5.00, which predicts an increase of 501.68% from the current stock price of 0.83.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Spero Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +501.68% | Jan 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $5 | Buy → Hold | Downgrades | $5 | +501.68% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +501.68% | Dec 2, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Nov 15, 2024 |
Financial Forecast
Revenue This Year
39.75M
from 103.78M
Decreased by -61.70%
Revenue Next Year
30.60M
from 39.75M
Decreased by -23.01%
EPS This Year
-0.94
from 0.43
EPS Next Year
-0.58
from -0.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 47.6M | 63.0M | 1.4M | |||
| Avg | 39.7M | 30.6M | 1.3M | |||
| Low | 31.9M | n/a | 1.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -54.1% | 58.5% | -95.5% | |||
| Avg | -61.7% | -23.0% | -95.7% | |||
| Low | -69.2% | - | -95.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.38 | -0.13 | -0.54 | |||
| Avg | -0.94 | -0.58 | -0.52 | |||
| Low | -1.21 | -0.82 | -0.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.